A phase /11 study of multicyclic dose-intensive chemotherapy supported with G-CSF, or Summary We investigated the reconstitutive potential of haematopoietic progenitor cells collected in autologous whole blood during multicycle dose-intensified chemotherapy. Forty patients with metastatic solid tumours were treated with up to six cycles of cisplatin and escalating doses of ifosfamide every 14 days. Cisplatin was administered in 3% sodium chloride over 3 h, followed by ifosfamide over 24 h and mesna over 36 h. The first cohort of patients received granulocyte colony-stimulating factor (G-CSF) days 4-14. Once dose-limiting toxicity was reached in cohort 1, the study continued with a second cohort of patients, in whom, in addition to G-CSF on days 4-14, 500 ml of G-CSF and chemotherapy-primed' whole blood was collected on day 15, i.e. on day 1 of treatment cycles two to six, before cisplatin administration. This volume of blood was kept unprocessed at 40C and reinfused 20-24 h after the completion of ifosfamide. In cohort 1, dose-limiting toxicity (DLT) was reached at ifosfamide 6.0 g m-2 with two out of six of the patients developing neutropenic fever. Although in cohort 2 no neutropenic fever was encountered, neither the frequency nor the duration of grade 4 neutropenia and thrombocytopenia were reduced. Cumulative asthenia resulted in DLT at 7.0 g m-2. The median number of CD34+ cells in 500 ml of whole blood after the first cycle (i.e. at start of cycle 2) was 1.15 x 106 kg-1. This number was significantly greater after the second cycle (2.06 x 106 kg-', P = 0.01) and then gradually decreased after cycles three to six. After storing whole blood, the number of CD34 + cells had not decreased (median + 10%). We conclude that the method of combined bone marrow support by G-CSF and haematopoietic progenitor cells in autologous whole blood collected before each cycle of a 2-weekly regimen of cisplatin-ifosfamide does not result in clinically measurable reduced bone marrow toxicity compared with what can be expected by the use of G-CSF alone.
The availability of peripheral blood haematopoietic progenitor cells (PBPCs) from different harvesting techniques and the possibilities of storage have raised interest in the administration of repetitive, closely spaced cycles of dose-intensive chemotherapy, each with PBPC rescue (Benjamin et al, 1995; Leyvraz et al, 1995; Pettengell et al, 1995; Vahdat et al, 1995; Rodenhuis et al, 1996) . It was previously reported that autologous whole blood (without processing through a cell separator) 'primed' with chemotherapy and granulocyte colony-stimulating factor (G-CSF) provided sufficient PBPCs for myelosupportive effects (Pettengell et al, 1994 (Pettengell et al, , 1995 Preti et al, 1994; Ossenkoppele et al, 1996) . In addition, PBPCs can be stored at 4°C for 48-72 h (Ossenkoppele et al, 1994 (Ossenkoppele et al, , 1996 Pettengell et al, 1994; Preti et al, 1994) . PBPCs can thus be harvested, kept unfrozen and reinfused after the administration of chemotherapy. We recently reported on a 2-weekly regimen of cisplatin-ifosfamide with G-CSF support (Planting et al, 1996) . In that study, haematological toxicity prevented the timely administration of the chemotherapy. In the present study, we investigated the feasibility and usefulness of PBPCs collected in G-CSF and chemotherapy-'primed' whole blood, by assessing the myelosupportive effects of G-CSF support alone, and G-CSF plus the reinfusion of PBPCs collected in 500 ml of autologous whole blood during each cycle of a modified 2-weekly regimen of cisplatin-ifosfamide chemotherapy.
PATIENTS AND METHODS
Eligibility required the histological proof of solid tumour for which cisplatin and ifosfamide were considered to be active agents, age < 70 years, WHO performance status 0-2, no previous chemotherapy, normal peripheral blood counts, creatinine clearance . 60 ml min-', serum bilirubin < 25 ,umol 1-', serum albumin 2 25 g 1-and written informed consent.
The chemotherapy consisted of cisplatin at a dose of 70 mg m-2 and escalating doses of ifosfamide starting at 5 g m-2 with 0.5-g dose increments per dose level. Prehydration consisted of 11 of dextrose/saline + 20 mmol potassium chloride and 2 g of magnesium sulphate. Cisplatin, dissolved in 250 ml of hypertonic saline (3% sodium chloride), was administered over 3 h, followed by ifosfamide plus mesna at two-thirds of the dose of ifosfamide in 4 1 of dextrose/saline + 60 mmol potassium chloride and 8 g of magnesium sulphate over 24 h. The remaining one-third of the dose of mesna was administered in another 2 1 dextrose/saline during the next 12 h. A maximum of six cycles per patient was planned. Subsequent cycles of chemotherapy were given if WBC . 2.0 x 109 1-and platelets . 60 x 109 1-1. The protocol did not allow dose reductions. Three to six patients were to be entered at each dose level. Dose-limiting toxicity (DLT) was defined as grade 4 neutropenia > 5 days or with fever > 38°C over a 12-h period or > 38.5°C once, or grade 4 thrombocytopenia with bleeding, or . grade 3 non-haematological toxicity occurring in . one of three or 2 two of six patients per dose level. Blood counts were measured thrice weekly. All cycles of treatment per patient were taken into account for defining DLT.
The first cohort of patients (cohort 1, G-CSF alone) received r-met Hu G-CSF (Filgrastim, Amgen, Breda, The Netherlands) subcutaneously at a dose of 5 ,ug kg-' once daily days 4-9, twice daily days 10-13 and a last dose in the morning of day 14. The higher daily dose of G-CSF on days 10-14 was based on its greater ability to stimulate endogenous marrow progenitor cells (Dreger et al, 1994) .
Once DLT was reached in cohort 1, the study continued with a second cohort (cohort 2), treated at the same dose levels as those of cohort 1 with the exception of the first dose level, with the intention to try and achieve a higher DLT. In cohort 2, in addition to G-CSF, 500 ml of autologous G-CSF 'primed' whole blood was collected by venesection on day 15, at the time of neutrophil recovery and maximum release of progenitor cells (Benjamin et al, 1995; Planting et al, 1996) i.e. day 1 of cycle two to six, before the administration of cisplatin. The blood was collected in CPD/ SAG-M (Biopack-compoflex NPB Emmer Compascum, The Netherlands) and cooled rapidly to 4°C in a refrigerator at the blood bank and kept at 40C without further processing. The blood British Journal of Cancer (1998) 77(12), [2363] [2364] [2365] [2366] . Cancer Research Campaign 1998 A phase 1/11 study of multicyclic dose-intensive chemotherapy 2365 
RESULTS
A total of 40 patients, median age 55 years (range 19-70 years) were treated. Of these, 15 had gastric adenocarcinoma, nine had poorly differentiated cancer of unknown primary site, five had malignant melanoma, and nine had miscellaneous metastatic solid tumours. Pretreatment characteristics including median age, sex, WHO performance status, peripheral blood cell counts at entry and distribution of tumour types were essentially identical for the two patient cohorts (data not shown).
In cohort 1, 15 patients received 67 cycles at ifosfamide doses of 5.0, 5.5 and 6.0 g m-2. Haematological toxicity is listed in Table 1 . Dose-limiting toxicity (DLT) was reached at 6.0 g m-2, with two out of six patients developing neutropenic fever.
Subsequently, in cohort 2, 25 patients received 87 cycles with ifosfamide at 5.5, 6.0, 6.5 and 7.0 g m-2. Haematological toxicity is given in Table 2 . Although no neutropenic fever was encountered, neither the frequency nor the duration (median 3 days in both cohorts) of grade 4 neutropenia and thrombocytopenia was reduced in comparison with cohort 1. Non-haematological toxicities and reasons for withdrawal are given in Table 3 . Cumulative asthenia resulted in DLT in cohort 2 at 7.0 g m-2.
As non-haematological toxicity was dose limiting in cohort 2, in order to make a better comparison between myelotoxicity encountered in cohort 1 and cohort 2, three additional patients at the ifosfamide dose of 6.0 g m-2 were entered in both cohorts. All cycles of treatment per patient were taken into account for defining DLT, but for each patient who did not complete a minimum of three cycles, an additional patient was entered. This resulted in a total of nine patients and 35 cycles at dose level 6.0 g m-2 in cohort 1, and 11 patients and 32 cycles at dose level 6.0 g m-2. The data for these patients have been included in Tables 1-3 . Figure 1 shows the median number of CD34+ cells in 500 ml of whole blood harvested at the time of cycles two to six. The median number of CD34+ cells in 500 ml of whole blood after the first cycle (i.e. at start of cycle 2) was 1.15 x lP kg-I body weight. This number was significantly greater after the second cycle (2.06 x 106 kg-', P=0.01) and then gradually decreased after cycles three to six. Although there was a wide range in the percentual difference 
DISCUSSION
There is a rationale for delivering dose-intensified chemotherapy during repetitive cycles (Gurney et al, 1993) . With the technical ability to increase the numbers of PBPCs in peripheral blood with G-CSF and chemotherapy, the approach of multiple cycles of dose-intensive chemotherapy each to be followed by progenitor cell reinfusion has become possible. For this purpose two different methods are being investigated. One technique is the harvest of progenitor cells by large-volume apheresis after conventionally dosed chemotherapy and cryopreserving the harvest in separate amounts, enabling progenitor cell support after each of subsequent dose-intensive cycles of chemotherapy (Benjamin et al, 1995; Leyvraz et al, 1995; Vahdat et al, 1995; Rodenhuis et al, 1996) . The second approach is the use of progenitor cells collected before each cycle of chemotherapy, which are kept refrigerated until the chemotherapy has been administered and cells can be reinfused. In addition, there is evidence that sufficient numbers of progenitor cells can be harvested in relatively small amounts of British Journal of Cancer (1998) (Ossenkoppele et al, 1994 (Ossenkoppele et al, , 1996 Pettengell et al, 1994 Pettengell et al, , 1995 . This approach would appear simple and cost-effective as it does neither require apheresis equipment nor cryopreservation of the cells. Furthermore, there is evidence of similar or even greater viability and colony-forming potential of short-term refrigerated cells compared with cryopreserved cells (Preti et al, 1994) .
We studied the latter approach using progenitor cells present in a collection of G-CSF and 500 ml of chemotherapy-'primed' autologous whole blood in a 2-weekly dose-intensified cisplatinifosfamide regimen. Although we were able to harvest significant numbers of CD34+ cells, especially during the initial cycles of chemotherapy, the reinfusion of these cells did not translate into a measurable reduction of the myelotoxic effects by the chemotherapy. It could be argued, however, that despite the increased dose of ifosfamide by 30% in cohort 2, the myelotoxicity with whole blood PBPCs at these dose levels of 6.5 and 7.0 g m-2 was very similar to that at the lower dose levels without PBPCs. Also no neutropenic fever was encountered in cohort 2.
Nonetheless, the reconstitutive potential of PBPCs in whole blood in this schedule appears limited. The explanation for this cannot be found in technical aspects, as the harvesting technique, the medium and the duration of storage at 4°C were the same as applied by two investigators who reported on the use of PBPCs in whole blood (Ossenkoppele et al, 1994 (Ossenkoppele et al, , 1996 Pettengell et al, 1995) . The same holds true for the number of progenitor cells collected and the percentage of viable cells remaining after storage. Although the numbers of CD34+ cells collected in 500 ml of blood in this study were slightly less than reported in the other studies in 500-750 ml of whole blood, the median number of CD34+ cells of 1.15 x 106 kg-' at the second cycle and 2.06 x 106 kg-' at the third cycle should enable better identifiable effects on the haemopoietic reconstitution during the course of treatment. Also, the time interval of 20-24 h between the completion of ifosfamide infusion and reinfusion of PBPCs appears to be a sufficient wash-out period.
We have recently reported that the administration of G-CSF within 48 h before the start of chemotherapy has a detrimental effect on the bone marrow toxicity . As, for successful PBPC collection, G-CSF needs to be continued until the time of collection, so as to keep the stem cells in the circulation, this finding is a clear disadvantage of the method of administering chemotherapy immediately after the harvest of PBPCs. In the present study, the last dose of G-CSF was administered approximately 24 h before the start of chemotherapy, thereby possibly resulting in harmful effects on the bone marrow. However, the continued administration of G-CSF in our study cannot be an explanation for the different findings by Pettengell et al (1995) and Ossenkoppele et al (1994 Ossenkoppele et al ( , 1996 , as in their studies G-CSF was also continued until or even within 24 h before the administration of chemotherapy (personal communication).
The alternative method of harvesting PBPCs by apheresis after one or two cycles of conventionally dosed chemotherapy and cryopreserving the cells in separate quantities for subsequent support of several of dose-intensive chemotherapy cycles appears a more attractive approach. We and others have demonstrated in patients with breast cancer and germ cell cancer that sufficient numbers of PBPCs can be collected by single apheresis to support three or four dose-intensive chemotherapy cycles (Bokemeyer et al, 1996; Rodenhuis et al, 1996) .
We conclude that the method of combined bone marrow support by G-CSF and PBPCs in autologous whole blood collected before each cycle of a 2-weekly cisplatin-ifosfamide regimen does not result in clinically measurable reduced bone marrow toxicity, compared with what can be expected of support by G-CSF alone.
